JP7789697B2 - Ｃｙｐ１１ａ１阻害剤 - Google Patents

Ｃｙｐ１１ａ１阻害剤

Info

Publication number
JP7789697B2
JP7789697B2 JP2022568879A JP2022568879A JP7789697B2 JP 7789697 B2 JP7789697 B2 JP 7789697B2 JP 2022568879 A JP2022568879 A JP 2022568879A JP 2022568879 A JP2022568879 A JP 2022568879A JP 7789697 B2 JP7789697 B2 JP 7789697B2
Authority
JP
Japan
Prior art keywords
compound
methylsulfonyl
alkyl
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022568879A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021229152A5 (https=
JP2023525137A (ja
JP2023525137A5 (https=
Inventor
ベッレ、ダビド ディン
クンプライネン、エサ
メケレ、ミッコ
ピエチケイネン、ペッカ
ワン、ショウミン
ヴォールファールト、ゲルド
Original Assignee
オリオン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリオン コーポレーション filed Critical オリオン コーポレーション
Publication of JP2023525137A publication Critical patent/JP2023525137A/ja
Publication of JPWO2021229152A5 publication Critical patent/JPWO2021229152A5/ja
Publication of JP2023525137A5 publication Critical patent/JP2023525137A5/ja
Priority to JP2025244683A priority Critical patent/JP2026048803A/ja
Application granted granted Critical
Publication of JP7789697B2 publication Critical patent/JP7789697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP2022568879A 2020-05-14 2021-05-12 Ｃｙｐ１１ａ１阻害剤 Active JP7789697B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025244683A JP2026048803A (ja) 2020-05-14 2025-12-10 Ｃｙｐ１１ａ１阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20205486 2020-05-14
FI20205486 2020-05-14
PCT/FI2021/050353 WO2021229152A1 (en) 2020-05-14 2021-05-12 Cyp11a1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025244683A Division JP2026048803A (ja) 2020-05-14 2025-12-10 Ｃｙｐ１１ａ１阻害剤

Publications (4)

Publication Number Publication Date
JP2023525137A JP2023525137A (ja) 2023-06-14
JPWO2021229152A5 JPWO2021229152A5 (https=) 2024-05-22
JP2023525137A5 JP2023525137A5 (https=) 2024-05-22
JP7789697B2 true JP7789697B2 (ja) 2025-12-22

Family

ID=76325569

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022568879A Active JP7789697B2 (ja) 2020-05-14 2021-05-12 Ｃｙｐ１１ａ１阻害剤
JP2025244683A Pending JP2026048803A (ja) 2020-05-14 2025-12-10 Ｃｙｐ１１ａ１阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025244683A Pending JP2026048803A (ja) 2020-05-14 2025-12-10 Ｃｙｐ１１ａ１阻害剤

Country Status (8)

Country Link
US (1) US20230192677A1 (https=)
EP (1) EP4149924A1 (https=)
JP (2) JP7789697B2 (https=)
KR (1) KR20230010723A (https=)
CN (1) CN115551831A (https=)
AU (1) AU2021269872A1 (https=)
CA (1) CA3178067A1 (https=)
WO (1) WO2021229152A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117242056A (zh) * 2021-03-26 2023-12-15 北京加科思新药研发有限公司 用作sting激动剂的新型化合物及其用途
PE20241583A1 (es) * 2021-09-28 2024-08-01 Orion Corp Inhibidor de cyp11a1 para su uso en el tratamiento del cancer de prostata
WO2023084158A1 (en) * 2021-11-10 2023-05-19 Orion Corporation Cyp11a1 inhibitors
CN115304591B (zh) * 2022-07-08 2024-10-01 广州中医药大学(广州中医药研究院) 一种桥环甾体合成酶抑制剂及其制备方法和应用
CN118307519A (zh) * 2023-01-06 2024-07-09 上海闻耐医药科技有限公司 一类cyp11a1抑制剂化合物及其制备方法和用途
WO2024199262A1 (zh) * 2023-03-29 2024-10-03 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
WO2024199421A1 (zh) * 2023-03-30 2024-10-03 山东轩竹医药科技有限公司 Cyp11a1抑制剂
CN121039123A (zh) * 2023-04-21 2025-11-28 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
AU2024270498A1 (en) * 2023-05-11 2025-11-27 Foshan Ionova Biotherapeutics Co., Inc. Novel compounds as cyp11a1 inhibitors and methods of use thereof
CN121605106A (zh) * 2023-07-27 2026-03-03 优领医药科技(香港)有限公司 Cyp11a1抑制剂
CN121889383A (zh) * 2023-09-08 2026-04-17 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用
WO2025168117A1 (zh) * 2024-02-08 2025-08-14 盛睿泽华医药科技（苏州）有限公司 一种多环化合物及其制备方法和应用
WO2025237211A1 (zh) * 2024-05-11 2025-11-20 辽宁海思科制药有限公司 一种cyp11a1抑制剂的晶型物及其制备方法和应用
WO2025247149A1 (zh) * 2024-05-27 2025-12-04 辽宁海思科制药有限公司 一种cyp11a1抑制剂的盐及其晶型、其制备方法和应用
WO2026002207A1 (en) * 2024-06-28 2026-01-02 Acerand Therapeutics (Hong Kong) Limited Heterocyclic compounds as cyp11a1 inhibitors
WO2026040949A1 (zh) * 2024-08-19 2026-02-26 辽宁海思科制药有限公司 一种cyp11a1抑制剂的药物组合物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519221A (ja) 2003-02-28 2006-08-24 エグゾニ・テラピューティック・ソシエテ・アノニム 化合物並びに細胞増殖性疾患、網膜症及び関節炎を処置する方法
WO2013056015A1 (en) 2011-10-14 2013-04-18 Incyte Corporation Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
WO2017014170A1 (ja) 2015-07-17 2017-01-26 武田薬品工業株式会社 複素環化合物
JP2020502229A (ja) 2016-12-22 2020-01-23 オリオン コーポレーション Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519221A (ja) 2003-02-28 2006-08-24 エグゾニ・テラピューティック・ソシエテ・アノニム 化合物並びに細胞増殖性疾患、網膜症及び関節炎を処置する方法
WO2013056015A1 (en) 2011-10-14 2013-04-18 Incyte Corporation Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
WO2017014170A1 (ja) 2015-07-17 2017-01-26 武田薬品工業株式会社 複素環化合物
JP2020502229A (ja) 2016-12-22 2020-01-23 オリオン コーポレーション Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry，2004年，47(25)，P.6349-6362

Also Published As

Publication number Publication date
EP4149924A1 (en) 2023-03-22
CA3178067A1 (en) 2021-11-18
KR20230010723A (ko) 2023-01-19
US20230192677A1 (en) 2023-06-22
AU2021269872A1 (en) 2022-11-24
JP2023525137A (ja) 2023-06-14
WO2021229152A1 (en) 2021-11-18
CN115551831A (zh) 2022-12-30
JP2026048803A (ja) 2026-03-17

Similar Documents

Publication Publication Date Title
JP7789697B2 (ja) Ｃｙｐ１１ａ１阻害剤
JP7828893B2 (ja) プロテインチロシンホスファターゼ分解剤及びその使用方法
KR102826021B1 (ko) Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
JP6383418B2 (ja) 置換ベンズアミド及びその使用方法
AU2018391675A1 (en) Sulphonyl urea derivatives as NLRP3 inflammasome modulators
JP5503663B2 (ja) ガンマセクレターゼモジュレータ
KR20220114065A (ko) 3-(5-메톡시-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
US11530213B2 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
BRPI0708264A2 (pt) piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
BR112019010164A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar aterosclerose, esteatose hepática, aterosclerose, diabetes mellitus tipo 2, obesidade, hiperlipidemia ou hipercolesterolemia.
WO2016100349A2 (en) Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
JP2013540792A (ja) オレキシン受容体アンタゴニストとして有用なジアザ−スピロ［５．５］ウンデカン類
JP7465883B2 (ja) ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
HK40009292A (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
HK40009292B (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
TW201910325A (zh) 吲哚衍生物及其用途
BR122024021737A2 (pt) Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251210

R150 Certificate of patent or registration of utility model

Ref document number: 7789697

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150